The recent €25.4m ($27.7m) private placement provides Erytech with a healthy cash balance, which should allow effective execution on the strategy to advance and accelerate Graspa/Eryasp in the US, to move development into front-line ALL (acute lymphoblastic leukemia) and to continue pursuing new indications. Two-year follow-up ALL data for Graspa were recently presented at ASH, reinforcing its potential as an effective, safe therapy for patients with few options in this indication. Our v
17 Dec 2015
Private placement to pursue Graspa strategy
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Private placement to pursue Graspa strategy
The recent €25.4m ($27.7m) private placement provides Erytech with a healthy cash balance, which should allow effective execution on the strategy to advance and accelerate Graspa/Eryasp in the US, to move development into front-line ALL (acute lymphoblastic leukemia) and to continue pursuing new indications. Two-year follow-up ALL data for Graspa were recently presented at ASH, reinforcing its potential as an effective, safe therapy for patients with few options in this indication. Our v